• Enoxaparin Sodium Injection Prefilled Syringe Ih, USP
  • Enoxaparin Sodium Injection Prefilled Syringe Ih, USP
  • Enoxaparin Sodium Injection Prefilled Syringe Ih, USP
  • Enoxaparin Sodium Injection Prefilled Syringe Ih, USP
  • Enoxaparin Sodium Injection Prefilled Syringe Ih, USP
  • Enoxaparin Sodium Injection Prefilled Syringe Ih, USP

Enoxaparin Sodium Injection Prefilled Syringe Ih, USP

Application: Internal Medicine
Usage Mode: Ih
Suitable for: Elderly, Adult
State: Liquid
Shape: Injection
Type: Organic Chemicals
Diamond Member Since 2022

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company

Basic Info.

Model NO.
0.4ml and 0.6ml
Pharmaceutical Technology
Chemical Synthesis
Ingredient
Enoxaparin Sodium
Standard
USP
Transport Package
Prefilled Syringe in Box and Carton
Specification
0.4ml: 4000AxaIU and 0.6ml: 6000AxaIU
Origin
P. R. China
HS Code
3004909099
Production Capacity
10 Million Vials/Year

Product Description

Enoxaparin Sodium Injection Prefilled Syringe Ih, USPEnoxaparin Sodium Injection Prefilled Syringe Ih, USPEnoxaparin Sodium Injection Prefilled Syringe Ih, USPEnoxaparin Sodium Injection Prefilled Syringe Ih, USPEnoxaparin Sodium Injection Prefilled Syringe Ih, USPIt is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):
in patients undergoing abdominal surgery who are at risk for thromboembolic complications;
in patients undergoing hip replacement surgery, during and following hospitalization;
in patients undergoing knee replacement surgery;
in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness; 

 

Treatment Of Acute Deep Vein Thrombosis:
the inpatient treatment of acute deep veiEnoxaparin Sodium Injection Prefilled Syringe Ih, USPEnoxaparin Sodium Injection Prefilled Syringe Ih, USPn thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium;
the outpatient treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium; 

It is indicated for the prophylaxis of ischemic complications of unstable angina and non- Q-wave myocardial infarction, when concurrently administered with aspirin.
when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute ST-segment elevation myocardial infarction (STEMI) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (PCI).

 

Send your message to this supplier

*From:
*To:
avatar Mr. Alan Shen
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now